obesity drug news today glp-1 october 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth The GLP-1 Access Gap: Mapping

When combining insights from Morningstar Sustainalytics ESG Risk Ratings and Morningstar Equity Research (depicted in Exhibit 1), we find that Pfizer PFE and Roche RHHBY stand out as potential top choices among potential future market entrants, whereas Novo Nordisk NVO appears undervalued among current players

Caramori, J.C.N

The cost of GLP-1 RAs remains a barrier, particularly in low- and middle-income countries

Chakravarthy M, Arguelles-Tello FA, Sun ALA, Elliott M, Acosta L, Rankin JE, et al

Novel indications for GLP-1 RAs outside type 2 diabetes, such as type 1 diabetes, neurodegenerative diseases, and psoriasis, are being explored

PPAR mRNA expression was significantly upregulated and protein levels were nearly 1.7-fold greater in mice treated with P5 or Ex4 when compared with vehicle-treated DIO mice (Fig